Arno Therapeutics
Arno Therapeutics is a publicly-traded biopharmaceutical company developing oncology therapeutics for cancer patients, headquartered in Parsippany, New Jersey, with 11-50 employees and a small-cap public listing on OTC pink.
- Company typePrivate
- Founded2023
- HeadquartersParsippany, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arno Therapeutics does
Arno Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic products for the treatment of cancer patients. Founded in 2000 and headquartered in Parsippany, New Jersey, the company operates with a small team of 11-50 employees and trades publicly on the OTC pink market under the ticker ARNI. The company has raised approximately $61.4 million across four disclosed funding rounds between 2010 and 2016, drawing capital from biotech-focused institutional investors including Perceptive Advisors, Soros Fund Management, Pontifax, Bellco Capital, and UTA Capital.
The company's leadership team is anchored by Founder and Co-founder David M. Tanen, who also serves as Secretary and Director, and Chairman of the Board Arie Belldegrun. Historical financial disclosures from 2011-2015 reflect substantial operating losses consistent with a pre-commercial oncology developer, with no revenue line items populated across the disclosed period and EBITDA losses reported each year. The most recent capital activity dates to August 2016, and the company's continued listing on OTC pink (rather than a senior exchange) combined with the absence of post-2016 funding or commercial milestones in the input data suggests limited recent operational momentum.
Note on data quality: A significant portion of the aggregated input describes "Arnothera" (arnothera.com), a privately-operated Gold IRA educational website founded in 2023. This appears to be a distinct entity that has been conflated with Arno Therapeutics in the input. The biopharmaceutical interpretation has been used for this analysis based on the firmographics, leadership, financial, and funding data, which are internally consistent with a small public oncology developer.
Arno Therapeutics firmographics
Firmographics- Name
- Arno Therapeutics
- Legal name
- Arnothera
- Website
- https://arnothera.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Arno Therapeutics is a publicly-traded biopharmaceutical company developing oncology therapeutics for cancer patients, headquartered in Parsippany, New Jersey, with 11-50 employees and a small-cap public listing on OTC pink.
- Ownership category
- akta.pro rank
Arno Therapeutics industry classification
Industry- Product category
- Oncology Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
- akta.pro secondary industry
- Urologic Oncology (HLAKAOAB)
Keywords
Where Arno Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Parsippany
- HQ country
- United States
- HQ region
- North America
Markets served
Arno Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Distribution channels1 record
Marketing channels4 records
Arno Therapeutics product offering
Product offeringCore offering
Arno Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of cancer patients. The company's work centers on identifying and advancing targeted oncology drug candidates through preclinical and clinical development. Operations are focused on oncology R&D with the goal of addressing unmet medical needs in cancer treatment.
Product overview
Arnothera is a financial information and education company that provides guidance on gold and precious metals IRAs for retirement planning. The core offerings consist of a Gold IRA (Precious Metals IRA) product that enables self-directed retirement accounts holding physical gold, silver, platinum, or palladium, supported by 401(k) to Gold IRA rollover/transfer services. These are complemented by financial education content including articles, worksheets, and guides covering retirement preparation, market volatility, and investment strategies.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology Therapeutics Pipeline A portfolio of clinical-stage targeted therapeutics developed for the treatment of cancer patients, addressing unmet needs in oncology through precision drug development. Targeted at biopharmaceutical partners, healthcare providers, and ultimately cancer patients.
Companies that use Arno Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
Arno Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Arno Therapeutics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights1 record
Arno Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Bayer: Markets Nubeqa and Xofigo in urologic oncology. Comparable incumbent shaping prostate cancer treatment paradigms.
- Pfizer: Global pharma with significant oncology franchise, including prostate cancer assets. Relevant incumbent comparator and potential acquirer profile.
- Astellas Pharma: Major pharmaceutical company with a leadership position in urologic oncology (Xtandi). Sets the competitive standard Arno's prostate cancer programs must surpass.
- Novartis: Major oncology franchise including Pluvicto in prostate cancer. Sets competitive bar and represents potential strategic acquirer of clinical assets.
- Bristol-Myers Squibb: Global oncology leader with active prostate cancer and solid tumor programs. Represents both competitive pressure and partnership/acquisition relevance.
- Johnson & Johnson: Owns Erleada and historically Zytiga in prostate cancer; broad oncology portfolio. Defines the standard-of-care benchmark Arno would compete against.
Direct peers
- ESSA Pharma: Clinical-stage biopharma focused on developing treatments for prostate cancer. Highly comparable to Arno Therapeutics given overlapping therapeutic area (urologic oncology), similar development stage, and analogous investor base.
- Veru Inc. Oncology-focused biopharma with prostate and breast cancer programs, including hormonal therapies. Direct comparator to Arno's onapristone approach in hormone-driven tumors.
- Tokai Pharmaceuticals: Developed galeterone for castration-resistant prostate cancer. Directly comparable specialty urologic oncology peer that experienced clinical-stage binary outcomes.
Emerging players
- Oncternal Therapeutics: Small-cap clinical-stage oncology company with a pipeline spanning prostate cancer and other solid tumors. Comparable in scale and clinical-stage positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Arno Therapeutics social profiles
Digital presenceArno Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arno Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Arno Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arno Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arno Therapeutics
What does Arno Therapeutics do?
Arno Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of cancer patients. The company's work centers on identifying and advancing targeted oncology drug candidates through preclinical and clinical development. Operations are focused on oncology R&D with the goal of addressing unmet medical needs in cancer treatment.
Is Arno Therapeutics a public or private company?
Arno Therapeutics is a private company. It is classified as public and is currently operating.
When was Arno Therapeutics founded?
Arno Therapeutics was founded in 2023. It employs 11 to 50 people.
Where is Arno Therapeutics based?
Arno Therapeutics is headquartered in Parsippany, United States, in the North America region.
Who are Arno Therapeutics's main competitors?
Broad incumbents on record are Bayer, Pfizer, Astellas Pharma, Novartis, Bristol-Myers Squibb and Johnson & Johnson. Direct peers are ESSA Pharma, Veru Inc. and Tokai Pharmaceuticals. Oncternal Therapeutics is listed as an emerging player.
Does Arno Therapeutics have an API?
No public API is recorded for Arno Therapeutics.
What industry is Arno Therapeutics in?
Arno Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAKAOAB, Urologic Oncology. Its NAICS code is 32541 and its SIC code is 2834.